RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed RE-LY Trial

June 3, 2014 updated by: Boehringer Ingelheim

RELY-ABLE Long Term Multi-center Extension of Dabigatran Treatment in Patients With Atrial Fibrillation Who Completed the RE-LY Trial and a Cluster Randomised Trial to Assess the Effect of a Knowledge Translation Intervention on Patient Outcomes

The purposes of this study are:

  1. To evaluate the long-term safety of dabigatran etexilate
  2. To assess the effect of a knowledge translation intervention on patient outcomes

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

5897

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Australia
    • New South Wales
      • Coffs Harbour, New South Wales, Australia
        • 1160.71.0508 Boehringer Ingelheim Investigational Site
      • Gosford, New South Wales, Australia
        • 1160.71.0510 Boehringer Ingelheim Investigational Site
    • Queensland
      • Milton, Queensland, Australia
        • 1160.71.0506 Boehringer Ingelheim Investigational Site
    • South Australia
      • Ashford, South Australia, Australia
        • 1160.71.0509 Boehringer Ingelheim Investigational Site
    • Tasmania
      • Launceston, Tasmania, Australia
        • 1160.71.0507 Boehringer Ingelheim Investigational Site
    • Victoria
      • Box Hill, Victoria, Australia
        • 1160.71.0504 Boehringer Ingelheim Investigational Site
      • Geelong, Victoria, Australia
        • 1160.71.0501 Boehringer Ingelheim Investigational Site
  • Austria
      • Graz, Austria
        • 1160.71.0543 Boehringer Ingelheim Investigational Site
      • Linz, Austria
        • 1160.71.0549 Boehringer Ingelheim Investigational Site
      • Wien, Austria
        • 1160.71.0541 Boehringer Ingelheim Investigational Site
      • Wien, Austria
        • 1160.71.0542 Boehringer Ingelheim Investigational Site
      • Wien, Austria
        • 1160.71.0545 Boehringer Ingelheim Investigational Site
      • Wien, Austria
        • 1160.71.0547 Boehringer Ingelheim Investigational Site
      • Wien, Austria
        • 1160.71.0548 Boehringer Ingelheim Investigational Site
      • Wr. Neustadt, Austria
        • 1160.71.0550 Boehringer Ingelheim Investigational Site
  • Belgium
      • Aalst, Belgium
        • 1160.71.0564 Boehringer Ingelheim Investigational Site
      • Brasschaat, Belgium
        • 1160.71.0572 Boehringer Ingelheim Investigational Site
      • Brussel, Belgium
        • 1160.71.0571 Boehringer Ingelheim Investigational Site
      • Bruxelles, Belgium
        • 1160.71.0581 Boehringer Ingelheim Investigational Site
      • Bruxelles, Belgium
        • 1160.71.0585 Boehringer Ingelheim Investigational Site
      • Edegem, Belgium
        • 1160.71.0563 Boehringer Ingelheim Investigational Site
      • Genk, Belgium
        • 1160.71.0578 Boehringer Ingelheim Investigational Site
      • Genk, Belgium
        • 1160.71.0587 Boehringer Ingelheim Investigational Site
      • Gent, Belgium
        • 1160.71.0574 Boehringer Ingelheim Investigational Site
      • Gilly, Belgium
        • 1160.71.0588 Boehringer Ingelheim Investigational Site
      • Hasselt, Belgium
        • 1160.71.0568 Boehringer Ingelheim Investigational Site
      • Leuven, Belgium
        • 1160.71.0561 Boehringer Ingelheim Investigational Site
      • Liège, Belgium
        • 1160.71.0579 Boehringer Ingelheim Investigational Site
      • Oostende, Belgium
        • 1160.71.0567 Boehringer Ingelheim Investigational Site
      • Roeselare, Belgium
        • 1160.71.0570 Boehringer Ingelheim Investigational Site
      • Tienen, Belgium
        • 1160.71.0566 Boehringer Ingelheim Investigational Site
      • Turnhout, Belgium
        • 1160.71.0562 Boehringer Ingelheim Investigational Site
  • Brazil
      • Campinas, Brazil
        • 1160.71.0644 Boehringer Ingelheim Investigational Site
      • Curitiba, Brazil
        • 1160.71.0650 Boehringer Ingelheim Investigational Site
      • Curitiba, Brazil
        • 1160.71.0651 Boehringer Ingelheim Investigational Site
      • Goiania, Brazil
        • 1160.71.0652 Boehringer Ingelheim Investigational Site
      • Sao Jose do Riio Preto, Brazil
        • 1160.71.0646 Boehringer Ingelheim Investigational Site
      • São José do Rio Preto, Brazil
        • 1160.71.0647 Boehringer Ingelheim Investigational Site
      • São Paulo, Brazil
        • 1160.71.0643 Boehringer Ingelheim Investigational Site
  • Bulgaria
      • Pleven, Bulgaria
        • 1160.71.0620 Boehringer Ingelheim Investigational Site
      • Sofia, Bulgaria
        • 1160.71.0611 Boehringer Ingelheim Investigational Site
      • Sofia, Bulgaria
        • 1160.71.0612 Boehringer Ingelheim Investigational Site
      • Sofia, Bulgaria
        • 1160.71.0615 Boehringer Ingelheim Investigational Site
      • Sofia, Bulgaria
        • 1160.71.0617 Boehringer Ingelheim Investigational Site
      • Sofia, Bulgaria
        • 1160.71.0618 Boehringer Ingelheim Investigational Site
      • Sofia, Bulgaria
        • 1160.71.0625 Boehringer Ingelheim Investigational Site
  • Canada
      • Quebec, Canada
        • 1160.71.0700 Boehringer Ingelheim Investigational Site
    • Alberta
      • Calgary, Alberta, Canada
        • 1160.71.0694 Boehringer Ingelheim Investigational Site
      • Calgary, Alberta, Canada
        • 1160.71.0696 Boehringer Ingelheim Investigational Site
    • British Columbia
      • Coquitlam, British Columbia, Canada
        • 1160.71.0680 Boehringer Ingelheim Investigational Site
      • Coquitlam, British Columbia, Canada
        • 1160.71.0712 Boehringer Ingelheim Investigational Site
      • Kelowna, British Columbia, Canada
        • 1160.71.0706 Boehringer Ingelheim Investigational Site
      • Nanaimo, British Columbia, Canada
        • 1160.71.0725 Boehringer Ingelheim Investigational Site
      • New Westminster, British Columbia, Canada
        • 1160.71.0691 Boehringer Ingelheim Investigational Site
      • Victoria, British Columbia, Canada
        • 1160.71.0714 Boehringer Ingelheim Investigational Site
    • Manitoba
      • Portage la Prairie, Manitoba, Canada
        • 1160.71.0701 Boehringer Ingelheim Investigational Site
    • Nova Scotia
      • Halifax, Nova Scotia, Canada
        • 1160.71.0703 Boehringer Ingelheim Investigational Site
    • Ontario
      • Burlington, Ontario, Canada
        • 1160.71.0674 Boehringer Ingelheim Investigational Site
      • Cambridge, Ontario, Canada
        • 1160.71.0702 Boehringer Ingelheim Investigational Site
      • Cambridge, Ontario, Canada
        • 1160.71.0720 Boehringer Ingelheim Investigational Site
      • Grimsby, Ontario, Canada
        • 1160.71.0692 Boehringer Ingelheim Investigational Site
      • Hamilton, Ontario, Canada
        • 1160.71.0697 Boehringer Ingelheim Investigational Site
      • Hamilton, Ontario, Canada
        • 1160.71.0710 Boehringer Ingelheim Investigational Site
      • Hamilton, Ontario, Canada
        • 1160.71.0719 Boehringer Ingelheim Investigational Site
      • Hamilton, Ontario, Canada
        • 1160.71.0721 Boehringer Ingelheim Investigational Site
      • Mississauga, Ontario, Canada
        • 1160.71.0708 Boehringer Ingelheim Investigational Site
      • Newmarket, Ontario, Canada
        • 1160.71.0688 Boehringer Ingelheim Investigational Site
      • Oshawa, Ontario, Canada
        • 1160.71.0672 Boehringer Ingelheim Investigational Site
      • Ottawa, Ontario, Canada
        • 1160.71.0687 Boehringer Ingelheim Investigational Site
      • Scarborough, Ontario, Canada
        • 1160.71.0679 Boehringer Ingelheim Investigational Site
      • Scarborough, Ontario, Canada
        • 1160.71.0723 Boehringer Ingelheim Investigational Site
      • Sudbury, Ontario, Canada
        • 1160.71.0715 Boehringer Ingelheim Investigational Site
      • Thunder Bay, Ontario, Canada
        • 1160.71.0690 Boehringer Ingelheim Investigational Site
      • Toronto, Ontario, Canada
        • 1160.71.0684 Boehringer Ingelheim Investigational Site
      • Toronto, Ontario, Canada
        • 1160.71.0718 Boehringer Ingelheim Investigational Site
      • Windsor, Ontario, Canada
        • 1160.71.0686 Boehringer Ingelheim Investigational Site
    • Quebec
      • Montreal, Quebec, Canada
        • 1160.71.0683 Boehringer Ingelheim Investigational Site
      • Montreal, Quebec, Canada
        • 1160.71.0705 Boehringer Ingelheim Investigational Site
      • Montreal, Quebec, Canada
        • 1160.71.0709 Boehringer Ingelheim Investigational Site
      • Montreal, Quebec, Canada
        • 1160.71.0716 Boehringer Ingelheim Investigational Site
      • Quebec City, Quebec, Canada
        • 1160.71.0717 Boehringer Ingelheim Investigational Site
      • St. Charles-Borromee, Quebec, Canada
        • 1160.71.0699 Boehringer Ingelheim Investigational Site
      • St. George-de-Beauce, Quebec, Canada
        • 1160.71.0713 Boehringer Ingelheim Investigational Site
      • St. Hyacinthe, Quebec, Canada
        • 1160.71.0675 Boehringer Ingelheim Investigational Site
    • Saskatchewan
      • Saskatoon, Saskatchewan, Canada
        • 1160.71.0673 Boehringer Ingelheim Investigational Site
      • Saskatoon, Saskatchewan, Canada
        • 1160.71.0678 Boehringer Ingelheim Investigational Site
  • China
      • Beijing, China
        • 1160.71.0771 Boehringer Ingelheim Investigational Site
      • Beijing, China
        • 1160.71.0772 Boehringer Ingelheim Investigational Site
      • Beijing, China
        • 1160.71.0773 Boehringer Ingelheim Investigational Site
      • Beijing, China
        • 1160.71.0774 Boehringer Ingelheim Investigational Site
      • Haerbin, China
        • 1160.71.0776 Boehringer Ingelheim Investigational Site
      • Hangzhou, China
        • 1160.71.0784 Boehringer Ingelheim Investigational Site
      • QingDao, China
        • 1160.71.0778 Boehringer Ingelheim Investigational Site
      • Shanghai, China
        • 1160.71.0781 Boehringer Ingelheim Investigational Site
      • Shanghai, China
        • 1160.71.0782 Boehringer Ingelheim Investigational Site
      • Shenyang, China
        • 1160.71.0777 Boehringer Ingelheim Investigational Site
      • Shijiazhuang, China
        • 1160.71.0780 Boehringer Ingelheim Investigational Site
  • Czech Republic
      • Modrice, Czech Republic
        • 1160.71.0816 Boehringer Ingelheim Investigational Site
      • Ostrava 1, Czech Republic
        • 1160.71.0820 Boehringer Ingelheim Investigational Site
      • Pardubice, Czech Republic
        • 1160.71.0818 Boehringer Ingelheim Investigational Site
      • Plzen-Bory, Czech Republic
        • 1160.71.0814 Boehringer Ingelheim Investigational Site
      • Praha 5, Czech Republic
        • 1160.71.0811 Boehringer Ingelheim Investigational Site
      • Praha 6, Czech Republic
        • 1160.71.0812 Boehringer Ingelheim Investigational Site
      • Praha 9, Czech Republic
        • 1160.71.0813 Boehringer Ingelheim Investigational Site
      • Pribram, Czech Republic
        • 1160.71.0817 Boehringer Ingelheim Investigational Site
      • Usti nad Orlici, Czech Republic
        • 1160.71.0819 Boehringer Ingelheim Investigational Site
  • Denmark
      • Aalborg, Denmark
        • 1160.71.0837 Boehringer Ingelheim Investigational Site
      • Aarhus C, Denmark
        • 1160.71.0835 Boehringer Ingelheim Investigational Site
      • Frederikssund, Denmark
        • 1160.71.0838 Boehringer Ingelheim Investigational Site
      • Helsingør, Denmark
        • 1160.71.0833 Boehringer Ingelheim Investigational Site
      • Herlev, Denmark
        • 1160.71.0834 Boehringer Ingelheim Investigational Site
      • Horsens, Denmark
        • 1160.71.0841 Boehringer Ingelheim Investigational Site
      • Hvidovre, Denmark
        • 1160.71.0832 Boehringer Ingelheim Investigational Site
      • Køge, Denmark
        • 1160.71.0840 Boehringer Ingelheim Investigational Site
      • Odense, Denmark
        • 1160.71.0831 Boehringer Ingelheim Investigational Site
      • Roskilde, Denmark
        • 1160.71.0839 Boehringer Ingelheim Investigational Site
      • Svendborg, Denmark
        • 1160.71.0836 Boehringer Ingelheim Investigational Site
  • Finland
      • Helsinki, Finland
        • 1160.71.0851 Boehringer Ingelheim Investigational Site
      • Jyväskylä, Finland
        • 1160.71.0859 Boehringer Ingelheim Investigational Site
      • Oulu, Finland
        • 1160.71.0854 Boehringer Ingelheim Investigational Site
      • Pori, Finland
        • 1160.71.0858 Boehringer Ingelheim Investigational Site
      • Tampere, Finland
        • 1160.71.0852 Boehringer Ingelheim Investigational Site
      • Turku, Finland
        • 1160.71.0853 Boehringer Ingelheim Investigational Site
  • France
      • ABBEVILLE cedex, France
        • 1160.71.875A Boehringer Ingelheim Investigational Site
      • Angers, France
        • 1160.71.882D Boehringer Ingelheim Investigational Site
      • Angers, France
        • 1160.71.882G Boehringer Ingelheim Investigational Site
      • Besle Sur Vilaine, France
        • 1160.71.879F Boehringer Ingelheim Investigational Site
      • Cholet, France
        • 1160.71.887A Boehringer Ingelheim Investigational Site
      • Château Gontier, France
        • 1160.71.882K Boehringer Ingelheim Investigational Site
      • Derval, France
        • 1160.71.879C Boehringer Ingelheim Investigational Site
      • Feneu, France
        • 1160.71.882H Boehringer Ingelheim Investigational Site
      • GRENOBLE Cédex 9, France
        • 1160.71.888A Boehringer Ingelheim Investigational Site
      • La Chapelle sur Erdre, France
        • 1160.71.879B Boehringer Ingelheim Investigational Site
      • Langres, France
        • 1160.71.874A Boehringer Ingelheim Investigational Site
      • Laval, France
        • 1160.71.884A Boehringer Ingelheim Investigational Site
      • Le Mesnil en Valée, France
        • 1160.71.880B Boehringer Ingelheim Investigational Site
      • Murs Erigne, France
        • 1160.71.880A Boehringer Ingelheim Investigational Site
      • Nantes, France
        • 1160.71.879A Boehringer Ingelheim Investigational Site
      • Nantes, France
        • 1160.71.879H Boehringer Ingelheim Investigational Site
      • Nantes, France
        • 1160.71.879S Boehringer Ingelheim Investigational Site
      • Parcay les Pins, France
        • 1160.71.880J Boehringer Ingelheim Investigational Site
      • Paris, France
        • 1160.71.871A Boehringer Ingelheim Investigational Site
      • Saint Aubin Des Chateaux, France
        • 1160.71.879E Boehringer Ingelheim Investigational Site
      • Segre, France
        • 1160.71.880D Boehringer Ingelheim Investigational Site
      • Tierce, France
        • 1160.71.882A Boehringer Ingelheim Investigational Site
      • Tierce, France
        • 1160.71.882B Boehringer Ingelheim Investigational Site
      • Tierce, France
        • 1160.71.882C Boehringer Ingelheim Investigational Site
      • Vieillevigne, France
        • 1160.71.879G Boehringer Ingelheim Investigational Site
      • Vihiers, France
        • 1160.71.880E Boehringer Ingelheim Investigational Site
  • Germany
      • Berlin, Germany
        • 1160.71.0932 Boehringer Ingelheim Investigational Site
      • Berlin, Germany
        • 1160.71.0948 Boehringer Ingelheim Investigational Site
      • Berlin, Germany
        • 1160.71.0962 Boehringer Ingelheim Investigational Site
      • Bochum, Germany
        • 1160.71.0940 Boehringer Ingelheim Investigational Site
      • Dortmund, Germany
        • 1160.71.0972 Boehringer Ingelheim Investigational Site
      • Essen, Germany
        • 1160.71.0934 Boehringer Ingelheim Investigational Site
      • Frankfurt am Main, Germany
        • 1160.71.0931 Boehringer Ingelheim Investigational Site
      • Heidelberg, Germany
        • 1160.71.0943 Boehringer Ingelheim Investigational Site
      • Köln, Germany
        • 1160.71.0963 Boehringer Ingelheim Investigational Site
      • Lahr, Germany
        • 1160.71.0946 Boehringer Ingelheim Investigational Site
      • Limburg, Germany
        • 1160.71.0944 Boehringer Ingelheim Investigational Site
      • Mainz, Germany
        • 1160.71.0951 Boehringer Ingelheim Investigational Site
      • Mannheim, Germany
        • 1160.71.0933 Boehringer Ingelheim Investigational Site
      • Mannheim, Germany
        • 1160.71.0945 Boehringer Ingelheim Investigational Site
      • Mannheim, Germany
        • 1160.71.0970 Boehringer Ingelheim Investigational Site
      • Witten, Germany
        • 1160.71.0937 Boehringer Ingelheim Investigational Site
      • Wuppertal, Germany
        • 1160.71.0966 Boehringer Ingelheim Investigational Site
  • Greece
      • Athens, Greece
        • 1160.71.0901 Boehringer Ingelheim Investigational Site
      • Kalamaria-Thessaloniki, Greece
        • 1160.71.0914 Boehringer Ingelheim Investigational Site
      • Larissa, Greece
        • 1160.71.0904 Boehringer Ingelheim Investigational Site
      • Thiva, Greece
        • 1160.71.0910 Boehringer Ingelheim Investigational Site
      • Trikala, Greece
        • 1160.71.0903 Boehringer Ingelheim Investigational Site
      • Voula - Athens, Greece
        • 1160.71.0905 Boehringer Ingelheim Investigational Site
  • Hong Kong
      • Kowloon, Hong Kong
        • 1160.71.1003 Boehringer Ingelheim Investigational Site
      • Kowloon, Hong Kong
        • 1160.71.1004 Boehringer Ingelheim Investigational Site
  • Hungary
      • Budapest, Hungary
        • 1160.71.1011 Boehringer Ingelheim Investigational Site
      • Budapest, Hungary
        • 1160.71.1012 Boehringer Ingelheim Investigational Site
      • Budapest, Hungary
        • 1160.71.1013 Boehringer Ingelheim Investigational Site
      • Budapest, Hungary
        • 1160.71.1014 Boehringer Ingelheim Investigational Site
      • Budapest, Hungary
        • 1160.71.1015 Boehringer Ingelheim Investigational Site
      • Budapest, Hungary
        • 1160.71.1016 Boehringer Ingelheim Investigational Site
      • Gyongyos, Hungary
        • 1160.71.1020 Boehringer Ingelheim Investigational Site
      • Komarom, Hungary
        • 1160.71.1017 Boehringer Ingelheim Investigational Site
      • Pecs, Hungary
        • 1160.71.1018 Boehringer Ingelheim Investigational Site
  • India
      • Ahmedabad, India
        • 1160.71.1057 Boehringer Ingelheim Investigational Site
      • Ahmedabad-52, India
        • 1160.71.1056 Boehringer Ingelheim Investigational Site
      • Bangalore, India
        • 1160.71.1065 Boehringer Ingelheim Investigational Site
      • Hyderabad, India
        • 1160.71.1062 Boehringer Ingelheim Investigational Site
      • Jaipur, Rajasthan, India
        • 1160.71.1073 Boehringer Ingelheim Investigational Site
      • Kerala, India
        • 1160.71.1067 Boehringer Ingelheim Investigational Site
      • Kottayam, India
        • 1160.71.1068 Boehringer Ingelheim Investigational Site
      • Lucknow, Uttar Pradesh, India
        • 1160.71.1055 Boehringer Ingelheim Investigational Site
      • Ludhiana, India
        • 1160.71.1051 Boehringer Ingelheim Investigational Site
      • Mysore, India
        • 1160.71.1072 Boehringer Ingelheim Investigational Site
      • Nagpur-12, India
        • 1160.71.1059 Boehringer Ingelheim Investigational Site
      • New Delhi, India
        • 1160.71.1052 Boehringer Ingelheim Investigational Site
      • Pune, Maharashtra, India
        • 1160.71.1070 Boehringer Ingelheim Investigational Site
  • Israel
      • Afula, Israel
        • 1160.71.1110 Boehringer Ingelheim Investigational Site
      • Afula, Israel
        • 1160.71.1121 Boehringer Ingelheim Investigational Site
      • Ashkelon, Israel
        • 1160.71.1111 Boehringer Ingelheim Investigational Site
      • Givatayim, Israel
        • 1160.71.1117 Boehringer Ingelheim Investigational Site
      • Hadera, Israel
        • 1160.71.1112 Boehringer Ingelheim Investigational Site
      • Haifa, Israel
        • 1160.71.1091 Boehringer Ingelheim Investigational Site
      • Haifa, Israel
        • 1160.71.1113 Boehringer Ingelheim Investigational Site
      • Haifa, Israel
        • 1160.71.1114 Boehringer Ingelheim Investigational Site
      • Haifa, Israel
        • 1160.71.1116 Boehringer Ingelheim Investigational Site
      • Haifa, Israel
        • 1160.71.1118 Boehringer Ingelheim Investigational Site
      • Holon, Israel
        • 1160.71.1105 Boehringer Ingelheim Investigational Site
      • Jerusalem, Israel
        • 1160.71.1101 Boehringer Ingelheim Investigational Site
      • Jerusalem, Israel
        • 1160.71.1104 Boehringer Ingelheim Investigational Site
      • Jerusalem, Israel
        • 1160.71.1106 Boehringer Ingelheim Investigational Site
      • Kfar Saba, Israel
        • 1160.71.1119 Boehringer Ingelheim Investigational Site
      • Petah Tikva, Israel
        • 1160.71.1096 Boehringer Ingelheim Investigational Site
      • Ramat Gan, Israel
        • 1160.71.1093 Boehringer Ingelheim Investigational Site
      • Ramat Gan, Israel
        • 1160.71.1094 Boehringer Ingelheim Investigational Site
      • Ramat Gan, Israel
        • 1160.71.1095 Boehringer Ingelheim Investigational Site
      • Rehovot, Israel
        • 1160.71.1100 Boehringer Ingelheim Investigational Site
      • Safed, Israel
        • 1160.71.1103 Boehringer Ingelheim Investigational Site
      • Tel Aviv, Israel
        • 1160.71.1120 Boehringer Ingelheim Investigational Site
      • Tel Aviv, Israel
        • 1160.71.1122 Boehringer Ingelheim Investigational Site
      • Tel-Aviv, Israel
        • 1160.71.1107 Boehringer Ingelheim Investigational Site
      • Tel-Aviv, Israel
        • 1160.71.1108 Boehringer Ingelheim Investigational Site
      • Tel-Aviv, Israel
        • 1160.71.1109 Boehringer Ingelheim Investigational Site
  • Italy
      • Arezzo, Italy
        • 1160.71.1169 Boehringer Ingelheim Investigational Site
      • Ascoli Piceno, Italy
        • 1160.71.1172 Boehringer Ingelheim Investigational Site
      • Sassari, Italy
        • 1160.71.1170 Boehringer Ingelheim Investigational Site
  • Korea, Republic of
      • Busan, Korea, Republic of
        • 1160.71.1585 Boehringer Ingelheim Investigational Site
      • Cheonan-si, Korea, Republic of
        • 1160.71.1586 Boehringer Ingelheim Investigational Site
      • Daegu, Korea, Republic of
        • 1160.71.1584 Boehringer Ingelheim Investigational Site
      • Daegu, Korea, Republic of
        • 1160.71.1591 Boehringer Ingelheim Investigational Site
      • Gwangju, Korea, Republic of
        • 1160.71.1590 Boehringer Ingelheim Investigational Site
      • Incheon, Korea, Republic of
        • 1160.71.1581 Boehringer Ingelheim Investigational Site
      • Seoul, Korea, Republic of
        • 1160.71.1582 Boehringer Ingelheim Investigational Site
      • Seoul, Korea, Republic of
        • 1160.71.1583 Boehringer Ingelheim Investigational Site
      • Seoul, Korea, Republic of
        • 1160.71.1589 Boehringer Ingelheim Investigational Site
      • Seoul, Korea, Republic of
        • 1160.71.1592 Boehringer Ingelheim Investigational Site
      • Seoul, Korea, Republic of
        • 1160.71.1593 Boehringer Ingelheim Investigational Site
  • Malaysia
      • Kuala Lumpur, Malaysia
        • 1160.71.1291 Boehringer Ingelheim Investigational Site
      • Kuala Lumpur, Malaysia
        • 1160.71.1292 Boehringer Ingelheim Investigational Site
  • Netherlands
      • 's Hertogenbosch, Netherlands
        • 1160.71.1337 Boehringer Ingelheim Investigational Site
      • Almelo, Netherlands
        • 1160.71.1344 Boehringer Ingelheim Investigational Site
      • Amsterdam, Netherlands
        • 1160.71.1331 Boehringer Ingelheim Investigational Site
      • Apeldoorn, Netherlands
        • 1160.71.1336 Boehringer Ingelheim Investigational Site
      • Breda, Netherlands
        • 1160.71.1332 Boehringer Ingelheim Investigational Site
      • Den Helder, Netherlands
        • 1160.71.1349 Boehringer Ingelheim Investigational Site
      • Deventer, Netherlands
        • 1160.71.1345 Boehringer Ingelheim Investigational Site
      • Dirksland, Netherlands
        • 1160.71.1360 Boehringer Ingelheim Investigational Site
      • Ede, Netherlands
        • 1160.71.1340 Boehringer Ingelheim Investigational Site
      • Eindhoven, Netherlands
        • 1160.71.1358 Boehringer Ingelheim Investigational Site
      • Enschede, Netherlands
        • 1160.71.1338 Boehringer Ingelheim Investigational Site
      • Goes, Netherlands
        • 1160.71.1343 Boehringer Ingelheim Investigational Site
      • Gorinchem, Netherlands
        • 1160.71.1347 Boehringer Ingelheim Investigational Site
      • Groningen, Netherlands
        • 1160.71.1333 Boehringer Ingelheim Investigational Site
      • Heerlen, Netherlands
        • 1160.71.1361 Boehringer Ingelheim Investigational Site
      • Hengelo, Netherlands
        • 1160.71.1339 Boehringer Ingelheim Investigational Site
      • Hilversum, Netherlands
        • 1160.71.1346 Boehringer Ingelheim Investigational Site
      • Hoorn, Netherlands
        • 1160.71.1356 Boehringer Ingelheim Investigational Site
      • Maastricht, Netherlands
        • 1160.71.1359 Boehringer Ingelheim Investigational Site
      • Meppel, Netherlands
        • 1160.71.1341 Boehringer Ingelheim Investigational Site
      • Rotterdam, Netherlands
        • 1160.71.1354 Boehringer Ingelheim Investigational Site
      • Sneek, Netherlands
        • 1160.71.1351 Boehringer Ingelheim Investigational Site
      • Tiel, Netherlands
        • 1160.71.1353 Boehringer Ingelheim Investigational Site
      • Tilburg, Netherlands
        • 1160.71.1352 Boehringer Ingelheim Investigational Site
      • Veldhoven, Netherlands
        • 1160.71.1350 Boehringer Ingelheim Investigational Site
      • Velp, Netherlands
        • 1160.71.1342 Boehringer Ingelheim Investigational Site
      • Zwijndrecht, Netherlands
        • 1160.71.1348 Boehringer Ingelheim Investigational Site
  • Norway
      • Gjøvik, Norway
        • 1160.71.1396 Boehringer Ingelheim Investigational Site
      • Moss, Norway
        • 1160.71.1393 Boehringer Ingelheim Investigational Site
      • Nordbyhagen, Norway
        • 1160.71.1395 Boehringer Ingelheim Investigational Site
      • Oslo, Norway
        • 1160.71.1391 Boehringer Ingelheim Investigational Site
      • Oslo, Norway
        • 1160.71.1397 Boehringer Ingelheim Investigational Site
      • RUD, Norway
        • 1160.71.1394 Boehringer Ingelheim Investigational Site
  • Philippines
      • Ermita Manila, Philippines
        • 1160.71.1422 Boehringer Ingelheim Investigational Site
      • Manila, Philippines
        • 1160.71.1421 Boehringer Ingelheim Investigational Site
      • Pasig City, Philippines
        • 1160.71.1424 Boehringer Ingelheim Investigational Site
      • Quezon City, Philippines
        • 1160.71.1423 Boehringer Ingelheim Investigational Site
      • Quezon City, Philippines
        • 1160.71.1425 Boehringer Ingelheim Investigational Site
  • Poland
      • Gdynia, Poland
        • 1160.71.1436 Boehringer Ingelheim Investigational Site
      • Gdynia, Poland
        • 1160.71.1437 Boehringer Ingelheim Investigational Site
      • Gdynia, Poland
        • 1160.71.1438 Boehringer Ingelheim Investigational Site
      • Pulawy, Poland
        • 1160.71.1433 Boehringer Ingelheim Investigational Site
      • Warsaw, Poland
        • 1160.71.1431 Boehringer Ingelheim Investigational Site
      • Warsaw, Poland
        • 1160.71.1432 Boehringer Ingelheim Investigational Site
      • Zabrze, Poland
        • 1160.71.1434 Boehringer Ingelheim Investigational Site
  • Portugal
      • Amadora, Portugal
        • 1160.71.1456 Boehringer Ingelheim Investigational Site
      • Carnaxide, Portugal
        • 1160.71.1451 Boehringer Ingelheim Investigational Site
      • Coimbra, Portugal
        • 1160.71.1454 Boehringer Ingelheim Investigational Site
      • Coimbra, Portugal
        • 1160.71.1459 Boehringer Ingelheim Investigational Site
      • Covilhã, Portugal
        • 1160.71.1457 Boehringer Ingelheim Investigational Site
      • Porto, Portugal
        • 1160.71.1455 Boehringer Ingelheim Investigational Site
  • Romania
      • Bucharest, Romania
        • 1160.71.1471 Boehringer Ingelheim Investigational Site
      • Bucharest, Romania
        • 1160.71.1472 Boehringer Ingelheim Investigational Site
  • Russian Federation
      • Moscow, Russian Federation
        • 1160.71.1501 Boehringer Ingelheim Investigational Site
      • Moscow, Russian Federation
        • 1160.71.1503 Boehringer Ingelheim Investigational Site
      • Moscow, Russian Federation
        • 1160.71.1504 Boehringer Ingelheim Investigational Site
      • Moscow, Russian Federation
        • 1160.71.1505 Boehringer Ingelheim Investigational Site
      • Moscow, Russian Federation
        • 1160.71.1507 Boehringer Ingelheim Investigational Site
      • Moscow, Russian Federation
        • 1160.71.1508 Boehringer Ingelheim Investigational Site
      • Moscow, Russian Federation
        • 1160.71.1509 Boehringer Ingelheim Investigational Site
      • Moscow, Russian Federation
        • 1160.71.1510 Boehringer Ingelheim Investigational Site
      • Moscow, Russian Federation
        • 1160.71.1511 Boehringer Ingelheim Investigational Site
      • St. Petersburg, Russian Federation
        • 1160.71.1512 Boehringer Ingelheim Investigational Site
      • St. Petersburg, Russian Federation
        • 1160.71.1513 Boehringer Ingelheim Investigational Site
      • St. Petersburg, Russian Federation
        • 1160.71.1514 Boehringer Ingelheim Investigational Site
  • Singapore
      • Singapore, Singapore
        • 1160.71.1531 Boehringer Ingelheim Investigational Site
  • Slovakia
      • Banska Bystrica, Slovakia
        • 1160.71.1548 Boehringer Ingelheim Investigational Site
      • Bratislava, Slovakia
        • 1160.71.1541 Boehringer Ingelheim Investigational Site
      • Bratislava, Slovakia
        • 1160.71.1542 Boehringer Ingelheim Investigational Site
      • Bratislava, Slovakia
        • 1160.71.1543 Boehringer Ingelheim Investigational Site
      • Kosice, Slovakia
        • 1160.71.1550 Boehringer Ingelheim Investigational Site
      • Zilina, Slovakia
        • 1160.71.1547 Boehringer Ingelheim Investigational Site
  • Sweden
      • Göteborg, Sweden
        • 1160.71.1633 Boehringer Ingelheim Investigational Site
      • Malmö, Sweden
        • 1160.71.1627 Boehringer Ingelheim Investigational Site
      • Norrköping, Sweden
        • 1160.71.1625 Boehringer Ingelheim Investigational Site
      • Nässjö, Sweden
        • 1160.71.1628 Boehringer Ingelheim Investigational Site
      • Stockholm, Sweden
        • 1160.71.1626 Boehringer Ingelheim Investigational Site
      • Stockholm, Sweden
        • 1160.71.1634 Boehringer Ingelheim Investigational Site
      • Umeå, Sweden
        • 1160.71.1624 Boehringer Ingelheim Investigational Site
      • Uppsala, Sweden
        • 1160.71.1621 Boehringer Ingelheim Investigational Site
      • Uppsala, Sweden
        • 1160.71.1635 Boehringer Ingelheim Investigational Site
      • Västerås, Sweden
        • 1160.71.1622 Boehringer Ingelheim Investigational Site
      • Örebro, Sweden
        • 1160.71.1623 Boehringer Ingelheim Investigational Site
  • Switzerland
      • Basel, Switzerland
        • 1160.71.1652 Boehringer Ingelheim Investigational Site
      • Bellinzona, Switzerland
        • 1160.71.1655 Boehringer Ingelheim Investigational Site
      • Bern, Switzerland
        • 1160.71.1651 Boehringer Ingelheim Investigational Site
      • Lugano, Switzerland
        • 1160.71.1654 Boehringer Ingelheim Investigational Site
  • Taiwan
      • Changhua, Taiwan
        • 1160.71.1680 Boehringer Ingelheim Investigational Site
      • Hualien, Taiwan
        • 1160.71.1683 Boehringer Ingelheim Investigational Site
      • Kaohsiung, Taiwan
        • 1160.71.1682 Boehringer Ingelheim Investigational Site
      • Taichung, Taiwan
        • 1160.71.1679 Boehringer Ingelheim Investigational Site
      • Tainan, Taiwan
        • 1160.71.1681 Boehringer Ingelheim Investigational Site
      • Taipei, Taiwan
        • 1160.71.1671 Boehringer Ingelheim Investigational Site
      • Taipei, Taiwan
        • 1160.71.1672 Boehringer Ingelheim Investigational Site
      • Taipei, Taiwan
        • 1160.71.1673 Boehringer Ingelheim Investigational Site
      • Taipei, Taiwan
        • 1160.71.1674 Boehringer Ingelheim Investigational Site
      • Taipei, Taiwan
        • 1160.71.1675 Boehringer Ingelheim Investigational Site
      • Taipei, Taiwan
        • 1160.71.1676 Boehringer Ingelheim Investigational Site
      • Taipei, Taiwan
        • 1160.71.1677 Boehringer Ingelheim Investigational Site
      • Taoyuan, Taiwan
        • 1160.71.1678 Boehringer Ingelheim Investigational Site
  • Thailand
      • Bangkok, Thailand
        • 1160.71.1701 Boehringer Ingelheim Investigational Site
      • Chiang Mai, Thailand
        • 1160.71.1703 Boehringer Ingelheim Investigational Site
      • Khon Kaen, Thailand
        • 1160.71.1704 Boehringer Ingelheim Investigational Site
  • United Kingdom
      • Birmingham, United Kingdom
        • 1160.71.1744 Boehringer Ingelheim Investigational Site
      • Chertsey, United Kingdom
        • 1160.71.1746 Boehringer Ingelheim Investigational Site
      • County Armagh, United Kingdom
        • 1160.71.1745 Boehringer Ingelheim Investigational Site
      • Kirkcaldy, Fife, United Kingdom
        • 1160.71.1755 Boehringer Ingelheim Investigational Site
      • London, United Kingdom
        • 1160.71.1741 Boehringer Ingelheim Investigational Site
      • Newcastle upon Tyne, United Kingdom
        • 1160.71.1742 Boehringer Ingelheim Investigational Site
      • Newport, United Kingdom
        • 1160.71.1751 Boehringer Ingelheim Investigational Site
      • Northampton, United Kingdom
        • 1160.71.1752 Boehringer Ingelheim Investigational Site
      • Romford, Essex, United Kingdom
        • 1160.71.1743 Boehringer Ingelheim Investigational Site
      • York, United Kingdom
        • 1160.71.1748 Boehringer Ingelheim Investigational Site
  • United States
    • Alabama
      • Birmingham, Alabama, United States
        • 1160.71.0046 Boehringer Ingelheim Investigational Site
      • Birmingham, Alabama, United States
        • 1160.71.0057 Boehringer Ingelheim Investigational Site
      • Birmingham, Alabama, United States
        • 1160.71.0211 Boehringer Ingelheim Investigational Site
      • Mobile, Alabama, United States
        • 1160.71.0115 Boehringer Ingelheim Investigational Site
    • Arizona
      • Lake Havasu City, Arizona, United States
        • 1160.71.0104 Boehringer Ingelheim Investigational Site
      • Tucson, Arizona, United States
        • 1160.71.0185 Boehringer Ingelheim Investigational Site
    • Arkansas
      • Hot Springs, Arkansas, United States
        • 1160.71.0038 Boehringer Ingelheim Investigational Site
      • Jonesboro, Arkansas, United States
        • 1160.71.0302 Boehringer Ingelheim Investigational Site
      • Little Rock, Arkansas, United States
        • 1160.71.0191 Boehringer Ingelheim Investigational Site
      • Little Rock, Arkansas, United States
        • 1160.71.0213 Boehringer Ingelheim Investigational Site
    • California
      • Carmichael, California, United States
        • 1160.71.0441 Boehringer Ingelheim Investigational Site
      • Fullerton, California, United States
        • 1160.71.0333 Boehringer Ingelheim Investigational Site
      • La Jolla, California, United States
        • 1160.71.0384 Boehringer Ingelheim Investigational Site
      • Lancaster, California, United States
        • 1160.71.0246 Boehringer Ingelheim Investigational Site
      • Merced, California, United States
        • 1160.71.0070 Boehringer Ingelheim Investigational Site
      • Oakland, California, United States
        • 1160.71.0349 Boehringer Ingelheim Investigational Site
      • Oceanside, California, United States
        • 1160.71.0016 Boehringer Ingelheim Investigational Site
      • Pasadena, California, United States
        • 1160.71.0459 Boehringer Ingelheim Investigational Site
      • Poway, California, United States
        • 1160.71.0270 Boehringer Ingelheim Investigational Site
      • Riverside, California, United States
        • 1160.71.0135 Boehringer Ingelheim Investigational Site
      • Sacramento, California, United States
        • 1160.71.0300 Boehringer Ingelheim Investigational Site
      • San Diego, California, United States
        • 1160.71.0284 Boehringer Ingelheim Investigational Site
      • Walnut Creek, California, United States
        • 1160.71.0379 Boehringer Ingelheim Investigational Site
    • Colorado
      • Colorado Springs, Colorado, United States
        • 1160.71.0321 Boehringer Ingelheim Investigational Site
      • Colorado Springs, Colorado, United States
        • 1160.71.0449 Boehringer Ingelheim Investigational Site
      • Denver, Colorado, United States
        • 1160.71.0360 Boehringer Ingelheim Investigational Site
      • Denver, Colorado, United States
        • 1160.71.0413 Boehringer Ingelheim Investigational Site
      • Fort Collins, Colorado, United States
        • 1160.71.0362 Boehringer Ingelheim Investigational Site
    • Connecticut
      • Bridgeport, Connecticut, United States
        • 1160.71.0278 Boehringer Ingelheim Investigational Site
      • Guilford, Connecticut, United States
        • 1160.71.0482 Boehringer Ingelheim Investigational Site
    • Florida
      • Boynton Beach, Florida, United States
        • 1160.71.0382 Boehringer Ingelheim Investigational Site
      • Brandon, Florida, United States
        • 1160.71.0056 Boehringer Ingelheim Investigational Site
      • Clearwater, Florida, United States
        • 1160.71.0296 Boehringer Ingelheim Investigational Site
      • Coral Springs, Florida, United States
        • 1160.71.0327 Boehringer Ingelheim Investigational Site
      • Daytona Beach, Florida, United States
        • 1160.71.0376 Boehringer Ingelheim Investigational Site
      • Fort Myers, Florida, United States
        • 1160.71.0074 Boehringer Ingelheim Investigational Site
      • Jacksonville, Florida, United States
        • 1160.71.0089 Boehringer Ingelheim Investigational Site
      • Jacksonville, Florida, United States
        • 1160.71.0232 Boehringer Ingelheim Investigational Site
      • Jacksonville, Florida, United States
        • 1160.71.0427 Boehringer Ingelheim Investigational Site
      • Lakeland, Florida, United States
        • 1160.71.0012 Boehringer Ingelheim Investigational Site
      • Miami, Florida, United States
        • 1160.71.0034 Boehringer Ingelheim Investigational Site
      • Orlando, Florida, United States
        • 1160.71.0227 Boehringer Ingelheim Investigational Site
      • Ormond Beach, Florida, United States
        • 1160.71.0095 Boehringer Ingelheim Investigational Site
      • Pensacola, Florida, United States
        • 1160.71.0037 Boehringer Ingelheim Investigational Site
      • Port Charlotte, Florida, United States
        • 1160.71.0137 Boehringer Ingelheim Investigational Site
      • Port Charlotte, Florida, United States
        • 1160.71.0417 Boehringer Ingelheim Investigational Site
      • Rockledge, Florida, United States
        • 1160.71.0332 Boehringer Ingelheim Investigational Site
      • Sarasota, Florida, United States
        • 1160.71.0385 Boehringer Ingelheim Investigational Site
      • St. Petersburg, Florida, United States
        • 1160.71.0015 Boehringer Ingelheim Investigational Site
      • St. Petersburg, Florida, United States
        • 1160.71.0339 Boehringer Ingelheim Investigational Site
      • Vero Beach, Florida, United States
        • 1160.71.0019 Boehringer Ingelheim Investigational Site
    • Georgia
      • Atlanta, Georgia, United States
        • 1160.71.0159 Boehringer Ingelheim Investigational Site
      • Augusta, Georgia, United States
        • 1160.71.0021 Boehringer Ingelheim Investigational Site
      • Conyers, Georgia, United States
        • 1160.71.0161 Boehringer Ingelheim Investigational Site
    • Illinois
      • Cicero, Illinois, United States
        • 1160.71.0218 Boehringer Ingelheim Investigational Site
      • Maywood, Illinois, United States
        • 1160.71.0438 Boehringer Ingelheim Investigational Site
      • Melrose Park, Illinois, United States
        • 1160.71.0331 Boehringer Ingelheim Investigational Site
      • Normal, Illinois, United States
        • 1160.71.0364 Boehringer Ingelheim Investigational Site
      • North Chicago, Illinois, United States
        • 1160.71.0109 Boehringer Ingelheim Investigational Site
      • Oak Lawn, Illinois, United States
        • 1160.71.0152 Boehringer Ingelheim Investigational Site
      • Rockford, Illinois, United States
        • 1160.71.0198 Boehringer Ingelheim Investigational Site
      • Winfield, Illinois, United States
        • 1160.71.0433 Boehringer Ingelheim Investigational Site
    • Indiana
      • Fort Wayne, Indiana, United States
        • 1160.71.0377 Boehringer Ingelheim Investigational Site
      • Indianapolis, Indiana, United States
        • 1160.71.0288 Boehringer Ingelheim Investigational Site
      • Indianapolis, Indiana, United States
        • 1160.71.0352 Boehringer Ingelheim Investigational Site
      • Indianapolis, Indiana, United States
        • 1160.71.0436 Boehringer Ingelheim Investigational Site
      • South Bend, Indiana, United States
        • 1160.71.0235 Boehringer Ingelheim Investigational Site
    • Iowa
      • Dubuque, Iowa, United States
        • 1160.71.0268 Boehringer Ingelheim Investigational Site
      • West Des Moines, Iowa, United States
        • 1160.71.0001 Boehringer Ingelheim Investigational Site
      • West Des Moines, Iowa, United States
        • 1160.71.0357 Boehringer Ingelheim Investigational Site
    • Kentucky
      • Lexington, Kentucky, United States
        • 1160.71.0422 Boehringer Ingelheim Investigational Site
      • Louisville, Kentucky, United States
        • 1160.71.0178 Boehringer Ingelheim Investigational Site
      • Louisville, Kentucky, United States
        • 1160.71.0397 Boehringer Ingelheim Investigational Site
      • Owensboro, Kentucky, United States
        • 1160.71.0310 Boehringer Ingelheim Investigational Site
    • Louisiana
      • Baton Rouge, Louisiana, United States
        • 1160.71.0144 Boehringer Ingelheim Investigational Site
      • Lafayette, Louisiana, United States
        • 1160.71.0018 Boehringer Ingelheim Investigational Site
      • New Iberia, Louisiana, United States
        • 1160.71.0132 Boehringer Ingelheim Investigational Site
    • Maine
      • Auburn, Maine, United States
        • 1160.71.0096 Boehringer Ingelheim Investigational Site
    • Maryland
      • Annapolis, Maryland, United States
        • 1160.71.0114 Boehringer Ingelheim Investigational Site
      • Baltimore, Maryland, United States
        • 1160.71.0023 Boehringer Ingelheim Investigational Site
      • Baltimore, Maryland, United States
        • 1160.71.0047 Boehringer Ingelheim Investigational Site
      • Baltimore, Maryland, United States
        • 1160.71.0079 Boehringer Ingelheim Investigational Site
      • Baltimore, Maryland, United States
        • 1160.71.0186 Boehringer Ingelheim Investigational Site
      • Baltimore, Maryland, United States
        • 1160.71.0194 Boehringer Ingelheim Investigational Site
      • Bel Air, Maryland, United States
        • 1160.71.0255 Boehringer Ingelheim Investigational Site
      • Columbia, Maryland, United States
        • 1160.71.0398 Boehringer Ingelheim Investigational Site
      • Rockville, Maryland, United States
        • 1160.71.0177 Boehringer Ingelheim Investigational Site
      • Salisbury, Maryland, United States
        • 1160.71.0073 Boehringer Ingelheim Investigational Site
      • Salisbury, Maryland, United States
        • 1160.71.0207 Boehringer Ingelheim Investigational Site
      • Takoma Park, Maryland, United States
        • 1160.71.0196 Boehringer Ingelheim Investigational Site
      • Towson, Maryland, United States
        • 1160.71.0187 Boehringer Ingelheim Investigational Site
      • Westminster, Maryland, United States
        • 1160.71.0052 Boehringer Ingelheim Investigational Site
    • Massachusetts
      • Haverhill, Massachusetts, United States
        • 1160.71.0443 Boehringer Ingelheim Investigational Site
      • Haverhill, Massachusetts, United States
        • 1160.71.0452 Boehringer Ingelheim Investigational Site
      • Natick, Massachusetts, United States
        • 1160.71.0029 Boehringer Ingelheim Investigational Site
      • North Dartmouth, Massachusetts, United States
        • 1160.71.0003 Boehringer Ingelheim Investigational Site
      • Worcester, Massachusetts, United States
        • 1160.71.0308 Boehringer Ingelheim Investigational Site
    • Michigan
      • Grand Blanc, Michigan, United States
        • 1160.71.0154 Boehringer Ingelheim Investigational Site
      • Lapeer, Michigan, United States
        • 1160.71.0205 Boehringer Ingelheim Investigational Site
      • Muskegon, Michigan, United States
        • 1160.71.0279 Boehringer Ingelheim Investigational Site
      • Petoskey, Michigan, United States
        • 1160.71.0445 Boehringer Ingelheim Investigational Site
      • Rochester Hills, Michigan, United States
        • 1160.71.0274 Boehringer Ingelheim Investigational Site
      • Saginaw, Michigan, United States
        • 1160.71.0165 Boehringer Ingelheim Investigational Site
      • Troy, Michigan, United States
        • 1160.71.0020 Boehringer Ingelheim Investigational Site
      • Ypsilanti, Michigan, United States
        • 1160.71.0188 Boehringer Ingelheim Investigational Site
    • Minnesota
      • Minneapolis, Minnesota, United States
        • 1160.71.0202 Boehringer Ingelheim Investigational Site
      • St. Paul, Minnesota, United States
        • 1160.71.0101 Boehringer Ingelheim Investigational Site
    • Mississippi
      • Gulfport, Mississippi, United States
        • 1160.71.0086 Boehringer Ingelheim Investigational Site
      • Tupelo, Mississippi, United States
        • 1160.71.0119 Boehringer Ingelheim Investigational Site
    • Missouri
      • Columbia, Missouri, United States
        • 1160.71.0055 Boehringer Ingelheim Investigational Site
      • Kansas City, Missouri, United States
        • 1160.71.0257 Boehringer Ingelheim Investigational Site
      • St. Charles, Missouri, United States
        • 1160.71.0336 Boehringer Ingelheim Investigational Site
      • St. Louis, Missouri, United States
        • 1160.71.0249 Boehringer Ingelheim Investigational Site
    • Montana
      • Kalispell, Montana, United States
        • 1160.71.0027 Boehringer Ingelheim Investigational Site
    • Nebraska
      • Omaha, Nebraska, United States
        • 1160.71.0110 Boehringer Ingelheim Investigational Site
    • Nevada
      • Henderson, Nevada, United States
        • 1160.71.0346 Boehringer Ingelheim Investigational Site
      • Las Vegas, Nevada, United States
        • 1160.71.0430 Boehringer Ingelheim Investigational Site
    • New Jersey
      • Browns Mills, New Jersey, United States
        • 1160.71.0142 Boehringer Ingelheim Investigational Site
      • Cherry Hill, New Jersey, United States
        • 1160.71.0221 Boehringer Ingelheim Investigational Site
      • Flemington, New Jersey, United States
        • 1160.71.0248 Boehringer Ingelheim Investigational Site
      • Oakland, New Jersey, United States
        • 1160.71.0478 Boehringer Ingelheim Investigational Site
      • Ocean, New Jersey, United States
        • 1160.71.0392 Boehringer Ingelheim Investigational Site
      • Westwood, New Jersey, United States
        • 1160.71.0254 Boehringer Ingelheim Investigational Site
      • Woodland Park, New Jersey, United States
        • 1160.71.0472 Boehringer Ingelheim Investigational Site
    • New York
      • Albany, New York, United States
        • 1160.71.0476 Boehringer Ingelheim Investigational Site
      • Bronx, New York, United States
        • 1160.71.0113 Boehringer Ingelheim Investigational Site
      • Bronx, New York, United States
        • 1160.71.0281 Boehringer Ingelheim Investigational Site
      • Cortlandt Manor, New York, United States
        • 1160.71.0044 Boehringer Ingelheim Investigational Site
      • Mineola, New York, United States
        • 1160.71.0229 Boehringer Ingelheim Investigational Site
      • Mineola, New York, United States
        • 1160.71.0451 Boehringer Ingelheim Investigational Site
      • New Rochelle, New York, United States
        • 1160.71.0183 Boehringer Ingelheim Investigational Site
      • Northport, New York, United States
        • 1160.71.0210 Boehringer Ingelheim Investigational Site
      • Poughkeepsie, New York, United States
        • 1160.71.0075 Boehringer Ingelheim Investigational Site
      • Troy, New York, United States
        • 1160.71.0414 Boehringer Ingelheim Investigational Site
      • Watertown, New York, United States
        • 1160.71.0356 Boehringer Ingelheim Investigational Site
      • Yonkers, New York, United States
        • 1160.71.0064 Boehringer Ingelheim Investigational Site
    • North Carolina
      • Asheville, North Carolina, United States
        • 1160.71.0353 Boehringer Ingelheim Investigational Site
      • Charlotte, North Carolina, United States
        • 1160.71.0080 Boehringer Ingelheim Investigational Site
      • Gastonia, North Carolina, United States
        • 1160.71.0350 Boehringer Ingelheim Investigational Site
      • High Point, North Carolina, United States
        • 1160.71.0173 Boehringer Ingelheim Investigational Site
      • Pinehurst, North Carolina, United States
        • 1160.71.0006 Boehringer Ingelheim Investigational Site
      • Statesville, North Carolina, United States
        • 1160.71.0002 Boehringer Ingelheim Investigational Site
      • Statesville, North Carolina, United States
        • 1160.71.0069 Boehringer Ingelheim Investigational Site
    • North Dakota
      • Grand Forks, North Dakota, United States
        • 1160.71.0102 Boehringer Ingelheim Investigational Site
      • Jamestown, North Dakota, United States
        • 1160.71.0222 Boehringer Ingelheim Investigational Site
    • Ohio
      • Akron, Ohio, United States
        • 1160.71.0203 Boehringer Ingelheim Investigational Site
      • Canal Fulton, Ohio, United States
        • 1160.71.0434 Boehringer Ingelheim Investigational Site
      • Cincinnati, Ohio, United States
        • 1160.71.0402 Boehringer Ingelheim Investigational Site
      • Cincinnati, Ohio, United States
        • 1160.71.0426 Boehringer Ingelheim Investigational Site
      • Cincinnati, Ohio, United States
        • 1160.71.0479 Boehringer Ingelheim Investigational Site
      • Cleveland, Ohio, United States
        • 1160.71.0263 Boehringer Ingelheim Investigational Site
      • Cleveland, Ohio, United States
        • 1160.71.0480 Boehringer Ingelheim Investigational Site
      • Columbus, Ohio, United States
        • 1160.71.0267 Boehringer Ingelheim Investigational Site
      • Dayton, Ohio, United States
        • 1160.71.0035 Boehringer Ingelheim Investigational Site
      • Fairview Park, Ohio, United States
        • 1160.71.0150 Boehringer Ingelheim Investigational Site
      • Kettering, Ohio, United States
        • 1160.71.0201 Boehringer Ingelheim Investigational Site
      • Lorain, Ohio, United States
        • 1160.71.0223 Boehringer Ingelheim Investigational Site
      • Lyndhurst, Ohio, United States
        • 1160.71.0214 Boehringer Ingelheim Investigational Site
      • Sandusky, Ohio, United States
        • 1160.71.0275 Boehringer Ingelheim Investigational Site
      • Westlake, Ohio, United States
        • 1160.71.0103 Boehringer Ingelheim Investigational Site
    • Oklahoma
      • Tulsa, Oklahoma, United States
        • 1160.71.0435 Boehringer Ingelheim Investigational Site
    • Oregon
      • Corvallis, Oregon, United States
        • 1160.71.0139 Boehringer Ingelheim Investigational Site
      • Eugene, Oregon, United States
        • 1160.71.0325 Boehringer Ingelheim Investigational Site
      • Springfield, Oregon, United States
        • 1160.71.0133 Boehringer Ingelheim Investigational Site
    • Pennsylvania
      • Allentown, Pennsylvania, United States
        • 1160.71.0301 Boehringer Ingelheim Investigational Site
      • Camp Hill, Pennsylvania, United States
        • 1160.71.0295 Boehringer Ingelheim Investigational Site
      • Hershey, Pennsylvania, United States
        • 1160.71.0294 Boehringer Ingelheim Investigational Site
      • Jenkintown, Pennsylvania, United States
        • 1160.71.0369 Boehringer Ingelheim Investigational Site
      • Lancaster, Pennsylvania, United States
        • 1160.71.0431 Boehringer Ingelheim Investigational Site
      • Langhorne, Pennsylvania, United States
        • 1160.71.0168 Boehringer Ingelheim Investigational Site
      • Meadowbrook, Pennsylvania, United States
        • 1160.71.0293 Boehringer Ingelheim Investigational Site
      • Norristown, Pennsylvania, United States
        • 1160.71.0394 Boehringer Ingelheim Investigational Site
      • Pittsburgh, Pennsylvania, United States
        • 1160.71.0466 Boehringer Ingelheim Investigational Site
      • Sellersville, Pennsylvania, United States
        • 1160.71.0208 Boehringer Ingelheim Investigational Site
      • Uniontown, Pennsylvania, United States
        • 1160.71.0465 Boehringer Ingelheim Investigational Site
      • Wynnewood, Pennsylvania, United States
        • 1160.71.0032 Boehringer Ingelheim Investigational Site
      • Wyomissing, Pennsylvania, United States
        • 1160.71.0067 Boehringer Ingelheim Investigational Site
    • South Carolina
      • Beaufort, South Carolina, United States
        • 1160.71.0007 Boehringer Ingelheim Investigational Site
      • Charleston, South Carolina, United States
        • 1160.71.0383 Boehringer Ingelheim Investigational Site
      • Greenville, South Carolina, United States
        • 1160.71.0313 Boehringer Ingelheim Investigational Site
      • Spartanburg, South Carolina, United States
        • 1160.71.0166 Boehringer Ingelheim Investigational Site
      • Summerville, South Carolina, United States
        • 1160.71.0008 Boehringer Ingelheim Investigational Site
    • Tennessee
      • Chattanooga, Tennessee, United States
        • 1160.71.0084 Boehringer Ingelheim Investigational Site
      • Clinton, Tennessee, United States
        • 1160.71.0474 Boehringer Ingelheim Investigational Site
      • Germantown, Tennessee, United States
        • 1160.71.0062 Boehringer Ingelheim Investigational Site
      • Johnson City, Tennessee, United States
        • 1160.71.0370 Boehringer Ingelheim Investigational Site
      • Nashville, Tennessee, United States
        • 1160.71.0395 Boehringer Ingelheim Investigational Site
    • Texas
      • Austin, Texas, United States
        • 1160.71.0129 Boehringer Ingelheim Investigational Site
      • Austin, Texas, United States
        • 1160.71.0410 Boehringer Ingelheim Investigational Site
      • Dallas, Texas, United States
        • 1160.71.0156 Boehringer Ingelheim Investigational Site
      • Fort Worth, Texas, United States
        • 1160.71.0315 Boehringer Ingelheim Investigational Site
      • Houston, Texas, United States
        • 1160.71.0447 Boehringer Ingelheim Investigational Site
      • Killeen, Texas, United States
        • 1160.71.0483 Boehringer Ingelheim Investigational Site
      • Lubbock, Texas, United States
        • 1160.71.0335 Boehringer Ingelheim Investigational Site
      • San Antonio, Texas, United States
        • 1160.71.0269 Boehringer Ingelheim Investigational Site
      • San Antonio, Texas, United States
        • 1160.71.0307 Boehringer Ingelheim Investigational Site
      • San Marcos, Texas, United States
        • 1160.71.0285 Boehringer Ingelheim Investigational Site
      • Tyler, Texas, United States
        • 1160.71.0367 Boehringer Ingelheim Investigational Site
    • Virginia
      • Charlottesville, Virginia, United States
        • 1160.71.0453 Boehringer Ingelheim Investigational Site
      • Chesapeake, Virginia, United States
        • 1160.71.0053 Boehringer Ingelheim Investigational Site
      • Fredericksburg, Virginia, United States
        • 1160.71.0428 Boehringer Ingelheim Investigational Site
      • Harrisonburg, Virginia, United States
        • 1160.71.0311 Boehringer Ingelheim Investigational Site
      • Newport News, Virginia, United States
        • 1160.71.0292 Boehringer Ingelheim Investigational Site
      • Salem, Virginia, United States
        • 1160.71.0220 Boehringer Ingelheim Investigational Site
      • Suffolk, Virginia, United States
        • 1160.71.0224 Boehringer Ingelheim Investigational Site
      • Winchester, Virginia, United States
        • 1160.71.0317 Boehringer Ingelheim Investigational Site
    • Washington
      • Bellingham, Washington, United States
        • 1160.71.0050 Boehringer Ingelheim Investigational Site
      • Burien, Washington, United States
        • 1160.71.0040 Boehringer Ingelheim Investigational Site
      • Spokane, Washington, United States
        • 1160.71.0250 Boehringer Ingelheim Investigational Site
      • Tacoma, Washington, United States
        • 1160.71.0256 Boehringer Ingelheim Investigational Site
      • Wenatchee, Washington, United States
        • 1160.71.0024 Boehringer Ingelheim Investigational Site
    • West Virginia
      • Clarksburg, West Virginia, United States
        • 1160.71.0169 Boehringer Ingelheim Investigational Site
      • Huntington, West Virginia, United States
        • 1160.71.0365 Boehringer Ingelheim Investigational Site
    • Wisconsin
      • Madison, Wisconsin, United States
        • 1160.71.0099 Boehringer Ingelheim Investigational Site
      • Milwaukee, Wisconsin, United States
        • 1160.71.0072 Boehringer Ingelheim Investigational Site
      • Milwaukee, Wisconsin, United States
        • 1160.71.0461 Boehringer Ingelheim Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion criteria:

Participation in RE-LY, requires long term anticoagulation, provides written informed consent

Exclusion criteria:

Permanent discontinuation of dabigatran during RE-LY

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: dabigatran dose 1
dabigatran high dose twice daily
Drug: dabigatran dose 1
dabigatran high dose twice daily
Experimental: dabigatran dose 2
dabigatran low dose twice daily
Drug: dabigatran dose 2
dabigatran low dose twice daily

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Major Bleeding, Annualized Rate of Subjects With Major Bleeds
Time Frame: up to 43 months

Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.

Major bleeding must have satisfied one or more of the following criteria:

  • Bleeding associated with a reduction in hemoglobin of at least 20 g/L
  • Required transfusion of at least 2 units of blood or packed cells
  • Symptomatic bleeding in a critical area or organ: intraocular, intraspinal, intramuscular with compartment syndrome, retroperitoneal, intra-articular, pericardial, gastrointestinal

Major bleed were classified as life-threatening if they met one or more of the following criteria:

  • Reduction in hemoglobin of at least 50 g/L
  • Transfusion of at least 4 units of blood or packed cells
  • Symptomatic intracranial bleeding, either subdural or intracerebral
  • Associated with hypotension requiring use of intravenous inotropic agents
  • Required surgical intervention to stop bleeding
  • Resulted in death
up to 43 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Stroke, Annualized Rate of Subjects With Stroke
Time Frame: up to 43 months

Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.

Stroke was an acute onset of a focal neurological deficit of presumed vascular origin lasting for 24 hours or more or resulting in death. The stroke was categorized as ischemic or hemorrhagic or cause unknown based on computerized tomography (CT), magnetic resonance (MR) scanning or autopsy. Fatal stroke was defined as death from any cause within 30 days of stroke. Severity of stroke was assessed by modified Rankin score at discharge from hospital
up to 43 months
Non CNS Systemic Embolism (SEE), Annualized Rate of Subjects With Non-CNS SEE
Time Frame: up to 43 months

Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.

Systemic embolism was an acute vascular occlusion of the extremities or any organ (kidneys, mesenteric arteries, spleen, retina or grafts), and was to be documented by angiography, surgery, scintigraphy, or autopsy.
up to 43 months
Pulmonary Embolism (PE), Annualized Rate of Subjects With PE
Time Frame: up to 43 months

Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.

Pulmonary Embolism was generally documented by one of the following:

  1. an intraluminal filling defect in segmental or more proximal branches on spiral CT scan
  2. an intraluminal filling defect or an extension of an existing defect or a sudden cutoff of vessels more than 2.5 mm in diameter on the pulmonary angiogram
  3. a perfusion defect of at least 75% of a segment with a local normal ventilation result (high-probability) on ventilation/perfusion lung scan (VPLS)
  4. inconclusive spiral CT, pulmonary angiography or lung scintigraphy with demonstration of DVT in the lower extremities by compression ultrasound or venography.
up to 43 months
Acute Myocardial Infarction (MI), Annualized Rate of Subjects With MI
Time Frame: up to 43 months

Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.

a. In subjects not undergoing PCI or CABG a subject should have fulfilled at least 2 of the following: i. Typical prolonged severe chest pain or related symptoms or signs suggestive of MI. ii. Elevation of troponin or CK-MB to more than upper level of normal (ULN) or, if CK-MB was elevated at baseline, re-elevation to more than 50% increase above the previous level. iii. Development of significant Q-waves in at least 2 adjacent ECG leads. b. After percutaneous coronary intervention (within 24h). c. After coronary artery bypass grafting (within 72h). d. Silent myocardial infarction. e. Myocardial infarction could also have been demonstrated at autopsy.
up to 43 months
Deep Vein Thrombosis, Annualized Rate of Subjects With DVT
Time Frame: up to 43 months

Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.

Deep Vein Thrombosis (DVT) was generally documented by one of the following:

  1. abnormal compression ultrasound (CUS),
  2. an intraluminal filling defect on venography.
up to 43 months
Death, Annualized Rate of Subject Death
Time Frame: up to 43 months

Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.

Deaths were classified as being vascular (sudden/arrhythmic, pump failure death, or other vascular, including bleeding) or non-vascular, due to other specified causes (e.g., malignancy), or of unknown etiology.
up to 43 months
Annualized Rate of Subjects With Composite Incidence of Stroke, Non CNS Systemic Embolism (SEE)
Time Frame: up to 43 months
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.
up to 43 months
Annualized Rate of Subjects With Composite Incidence of Stroke, Non CNS Systemic Embolism (SEE) and All Cause Death
Time Frame: up to 43 months
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.
up to 43 months
Annualized Rate of Subjects With Composite Incidence of Stroke, Non CNS Systemic Embolism (SEE), Pulmonary Embolism (PE), Myocardial Infarction, Vascular Death
Time Frame: up to 43 months
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.
up to 43 months
Annualized Rate of Subjects With Composite Incidence of Stroke, Non CNS Systemic Embolism (SEE), Pulmonary Embolism (PE), Myocardial Infarction (MI), All Cause Death and Major Bleed
Time Frame: up to 43 months
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.
up to 43 months
Annualized Rate of Subjects With Minor Bleeds
Time Frame: up to 43 months

Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.

Minor bleeds were clinical bleeds that did not fulfill the criteria for major bleeds. Minor bleeds were classified as associated with study medication discontinuation (temporary or permanent) or not.
up to 43 months
Annualized Rate of Subjects With Any Bleeds (Major Plus Minor)
Time Frame: up to 43 months
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.
up to 43 months
Annualized Rate of Subjects With Intra-Cranial Hemorrhage (ICH)
Time Frame: up to 43 months
Annualized event rate (%) = 100 * No. subjects with event / subject-years. Subject-years = Sum (date of last visit - date of first dose + 1) of all subjects / 365.25.
up to 43 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Boehringer Ingelheim

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2008

Primary Completion (Actual)

December 1, 2012

Study Completion (Actual)

December 1, 2012

Study Registration Dates

First Submitted

December 12, 2008

First Submitted That Met QC Criteria

December 12, 2008

First Posted (Estimate)

December 15, 2008

Study Record Updates

Last Update Posted (Estimate)

June 9, 2014

Last Update Submitted That Met QC Criteria

June 3, 2014

Last Verified

March 1, 2014

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1160.71
  • 2008-005248-17 (EudraCT Number: EudraCT)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Atrial Fibrillation

Clinical Trials on dabigatran dose 1

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Madagascar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe